These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
467 related articles for article (PubMed ID: 12656692)
1. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Kim HJ; Camilleri M; McKinzie S; Lempke MB; Burton DD; Thomforde GM; Zinsmeister AR Aliment Pharmacol Ther; 2003 Apr; 17(7):895-904. PubMed ID: 12656692 [TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Kim HJ; Vazquez Roque MI; Camilleri M; Stephens D; Burton DD; Baxter K; Thomforde G; Zinsmeister AR Neurogastroenterol Motil; 2005 Oct; 17(5):687-96. PubMed ID: 16185307 [TBL] [Abstract][Full Text] [Related]
3. 5-HT4 receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit. Houghton LA; Jackson NA; Whorwell PJ; Cooper SM Aliment Pharmacol Ther; 1999 Nov; 13(11):1437-44. PubMed ID: 10571599 [TBL] [Abstract][Full Text] [Related]
4. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Kellow J; Lee OY; Chang FY; Thongsawat S; Mazlam MZ; Yuen H; Gwee KA; Bak YT; Jones J; Wagner A Gut; 2003 May; 52(5):671-6. PubMed ID: 12692051 [TBL] [Abstract][Full Text] [Related]
5. Abnormalities of GI transit in bloated irritable bowel syndrome: effect of bran on transit and symptoms. Hebden JM; Blackshaw E; D'Amato M; Perkins AC; Spiller RC Am J Gastroenterol; 2002 Sep; 97(9):2315-20. PubMed ID: 12358250 [TBL] [Abstract][Full Text] [Related]
6. A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): effects on symptoms, colonic transit and quality of life. Cappello C; Tremolaterra F; Pascariello A; Ciacci C; Iovino P Int J Colorectal Dis; 2013 Mar; 28(3):349-58. PubMed ID: 22885882 [TBL] [Abstract][Full Text] [Related]
7. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Steadman CJ; Talley NJ; Phillips SF; Zinsmeister AR Mayo Clin Proc; 1992 Aug; 67(8):732-8. PubMed ID: 1434911 [TBL] [Abstract][Full Text] [Related]
8. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. Thumshirn M; Coulie B; Camilleri M; Zinsmeister AR; Burton DD; Van Dyke C Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042 [TBL] [Abstract][Full Text] [Related]
9. Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of the Probiotic Bifidobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating. Ringel-Kulka T; McRorie J; Ringel Y Am J Gastroenterol; 2017 Jan; 112(1):145-151. PubMed ID: 27845337 [TBL] [Abstract][Full Text] [Related]
10. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506 [TBL] [Abstract][Full Text] [Related]
11. Naloxone treatment for irritable bowel syndrome--a randomized controlled trial with an oral formulation. Hawkes ND; Rhodes J; Evans BK; Rhodes P; Hawthorne AB; Thomas GA Aliment Pharmacol Ther; 2002 Sep; 16(9):1649-54. PubMed ID: 12197844 [TBL] [Abstract][Full Text] [Related]
12. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Gorard DA; Libby GW; Farthing MJ Aliment Pharmacol Ther; 1994 Apr; 8(2):159-66. PubMed ID: 8038347 [TBL] [Abstract][Full Text] [Related]
13. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. O'Sullivan MA; O'Morain CA Dig Liver Dis; 2000 May; 32(4):294-301. PubMed ID: 11515626 [TBL] [Abstract][Full Text] [Related]
14. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Camilleri M; Mayer EA; Drossman DA; Heath A; Dukes GE; McSorley D; Kong S; Mangel AW; Northcutt AR Aliment Pharmacol Ther; 1999 Sep; 13(9):1149-59. PubMed ID: 10468696 [TBL] [Abstract][Full Text] [Related]
15. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Houghton LA; Foster JM; Whorwell PJ Aliment Pharmacol Ther; 2000 Jun; 14(6):775-82. PubMed ID: 10848662 [TBL] [Abstract][Full Text] [Related]
16. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Prather CM; Camilleri M; Zinsmeister AR; McKinzie S; Thomforde G Gastroenterology; 2000 Mar; 118(3):463-8. PubMed ID: 10702196 [TBL] [Abstract][Full Text] [Related]
17. Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome. Vicari E; Salemi M; Sidoti G; Malaguarnera M; Castiglione R Nutrients; 2017 Nov; 9(11):. PubMed ID: 29099760 [TBL] [Abstract][Full Text] [Related]
18. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. Guandalini S; Magazzù G; Chiaro A; La Balestra V; Di Nardo G; Gopalan S; Sibal A; Romano C; Canani RB; Lionetti P; Setty M J Pediatr Gastroenterol Nutr; 2010 Jul; 51(1):24-30. PubMed ID: 20453678 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial. Han K; Wang J; Seo JG; Kim H J Gastroenterol; 2017 Apr; 52(4):432-443. PubMed ID: 27178566 [TBL] [Abstract][Full Text] [Related]
20. Melatonin regulation as a possible mechanism for probiotic (VSL#3) in irritable bowel syndrome: a randomized double-blinded placebo study. Wong RK; Yang C; Song GH; Wong J; Ho KY Dig Dis Sci; 2015 Jan; 60(1):186-94. PubMed ID: 25092036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]